According to Jin10, Hansoh Pharmaceutical said the European Commission revoked the EU marketing authorization for amethystine mesylate tablets, adding that the decision was not related to the drug's quality, safety, or efficacy but to a procedural issue in the regulatory review process. The company said it will restart the EU marketing authorization application as soon as possible and will continue to pursue its innovation and internationalization strategy. Hansoh Pharmaceutical also said the product has not yet generated actual overseas sales, and the UK approval obtained in 2025 remains valid.